Ångstrom Pharmaceuticals, Inc., a privately held pharmaceutical company headquartered in San Diego, California, is developing a new class of drugs targeting CD44 for the treatment of metastatic diseases and hematological malignancies. Ångstrom's lead product, Å6 peptide, is in Phase 2 clinical development.


Å6 Phase 2 Chronic Lymphocytic Leukemia Clinical Trial
Å6 AACR Abstract - 2014 Annual Meeting